Key result
Beta-1 adrenoceptor polymorphisms have an ongoing debated role regarding clinical outcomes and the beneficial effects of beta-blockers in patients with heart failure.
Why the study?
Do beta(1)-adrenoceptor polymorphisms affect the clinical outcomes and beneficial effects of beta-blockers in patients with heart failure?
Do beta(1)-adrenoceptor polymorphisms affect the clinical outcomes and beneficial effects of beta-blockers in patients with heart failure?
Answers are grounded in this paper and cite their sources.
This article calls for a closer examination of the peer-reviewed evidence regarding the impact of beta1-adrenoceptor polymorphisms on beta-blocker efficacy in heart failure.
While the debate continues regarding the role of polymorphisms of beta(1)-adrenoceptors on the clinical outcomes and beneficial effects of beta-blockers in patients with heart failure, we need to step back and examine the evidence in the peer-reviewed literature more closely.
No takes yet. Share an insight, caveat, or question.
Reza Tabrizchi (2008) studied this question. Beta-1 adrenoceptor polymorphisms have an ongoing debated role regarding clinical outcomes and the beneficial effects of beta-blockers in patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: